Else Nutrition
Northstar Clean Technologies

Plug Into More Green Stock News

Tap into the pulse of emerging green sectors every morning. Top daily headlines from clean energy, cleantech, cannabis, and sustainable transport stocks:

Please review our Disclaimer and Privacy Policy before subscribing. One-click unsubscribe at any time.

Cansortium Reports Second Quarter 2022 Financial Results

  • Q2 Revenue up 14% QoQ and 36% YoY to a Record $22.4 Million 
  • Q2 Adjusted EBITDA up 64% QoQ and 95% YoY to a Record $10.2 Million, with $4.3 Million of
    Cash from Operations 
  • Reaffirms 2022 Guidance of $90-$95 Million of Revenue and $25-$28 Million of
    Adjusted EBITDA 

Cansortium Inc. (CSE:TIUM.U) (OTCQX: CNTMF) ("Cansortium" or the "Company"), a vertically-integrated cannabis company operating under the Fluent™ brand, today announced financial and operating results for the second quarter ended June 30, 2022. Unless otherwise indicated, all results are presented in U.S. dollars.

"We generated a record quarter of results in Q2, highlighted by double-digit revenue growth, margin expansion and a material increase in adjusted EBITDA and cash flow generation," said CEO Robert Beasley. "The investments we have made to add scale and improve cultivation in Florida are paying dividends. Our Sweetwater indoor cultivation facility is now fully operational and the yields in our Tampa facility have doubled from the start of 2022, all of which has led to dramatically improved productivity at the store level and a consistent increase in new patient count. In fact, revenue in Florida was up 16% from Q1 without adding a single new store during the quarter."

Beasley continued: "I am very proud of what our team has accomplished this year, however we still have significant room to grow. We remain on track to open 4-5 new stores in Florida by year-end, and the final phase of our cultivation expansion in Tampa is nearly complete. We expect product from this new space to hit shelves in the next couple of months, just in time for one of our strongest periods of the year in Florida as we enter the holidays."

Q2 2022 Financial Highlights (vs. Q2 2021)

  • Revenue increased 36% to $22.4 million compared to $16.5 million.
  • Florida revenue increased 33% to $18.8 million compared to $14.2 million.
  • Adjusted gross profit1 increased 40% to $15.0 million or 67.0% of revenue, compared to $10.7 million or 65.1% of revenue.
  • Adjusted EBITDA increased 95% to $10.2 million or 45.4% of revenue, compared to $5.2 million or 31.7% of revenue.
  • Cash from operations increased significantly to $4.3 million compared to cash used of $(0.7) million.
  • At June 30, 2022, the Company had approximately $8.9 million of cash and cash equivalents and $69.3 million of total debt, with approximately 252.3 million fully diluted shares outstanding (based on treasury stock method and share price on July 31, 2022).

Operational Highlights

  • In Florida, the Company anticipates opening 4-5 new stores by the end of 2022. All of these locations are currently under contract and going through construction.
  • In Pennsylvania, the Company opened its third dispensary in Annville in April.
  • In August, the Company discontinued its operations in Michigan due to unfavorable market conditions. By ceasing operations in Michigan, Cansortium is expected to save approximately $0.5 million in operating expenses per year.
  • As highlighted in the chart below, the Company has experienced ten consecutive quarters of revenue growth in addition to material improvements in adjusted EBITDA, reaching record levels for both metrics.

Revenue and Adjusted EBITDA (CNW Group/Cansortium Inc)

______________________________

1 Adjusted gross profit is a non-IFRS financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. The Company calculates adjusted gross profit from gross profit plus (minus) the changes in fair value of biological assets, as presented in the consolidated statement of operations.

2022 Outlook

The Company continues to expect revenue in 2022 to range between $90-$95 million, reflecting an approximate 42% increase from 2021 at the midpoint. Cansortium also continues to expect adjusted EBITDA in 2022 to range between $25-$28 million, reflecting an approximate 35% increase from 2021.

Conference Call

The Company will host a conference call and live audio webcast today at 4:30 p.m. Eastern time to discuss its financial and operational results, followed by a question-and-answer period.

Date: Monday, August 29, 2022 
Time: 4:30 p.m. Eastern time
Toll-free dial-in number: (800) 319-4610
International dial-in number: (604) 638-5340
Conference ID: 10020139 
Link: Cansortium Conference Call

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Elevate IR at (720) 330-2829.

The conference call will also be available for replay via the News & Events section of the Company's investor relations website at https://investors.getfluent.com/.

About Cansortium Inc.

Cansortium is a vertically-integrated cannabis company with licenses and operations in Florida, Pennsylvania and Texas. The Company operates under the Fluent™ brand and is dedicated to being one of the highest quality cannabis companies for the communities it serves. This is driven by Cansortium's unrelenting commitment to operational excellence in cultivation, production, distribution and retail. The Company is headquartered in Miami, Florida.

Cansortium Inc.'s common shares trade on the CSE under the symbol "TIUM.U" and on the OTCQX Best Market under the symbol "CNTMF". For more information about the Company, please visit www.getfluent.com.

Forward-Looking Information

Certain information in this news release may constitute forward-looking information within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent the Company's expectations, estimates, and projections regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control.

Forward-looking information is necessarily based on many opinions, assumptions, and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in the public documents of the Company available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

For further information: www.getfluent.com.

Company Contact 
Robert Beasley, CEO 
(850) 972-8077 
investors.getfluent.com

Investor Relations Contact 
Sean Mansouri, CFA 
Elevate IR 
(720) 330-2829
This email address is being protected from spambots. You need JavaScript enabled to view it.

CANSORTIUM INC.

      

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

As of June 30, 2022 and December 31, 2021

 

(USD '000)

      
       
       
    

June 30,
2022

 

December 31,
2021

Assets

      

Current assets

      

Cash and cash equivalents

$            8,858

 

$                 9,024

Trade receivable

   

59

 

26

Inventory, net

   

12,209

 

8,981

Biological assets

   

4,118

 

3,297

Investment held for sale

 

200

 

200

Prepaid expenses and other current assets

1,178

 

2,007

Total current assets

   

26,622

 

23,535

       
       

Property and equipment, net

33,846

 

34,160

Intangible assets, net

   

95,057

 

95,822

Right-of-use assets, net

 

19,480

 

19,169

Note receivable

   

-

 

4,886

Deposit

   

-

 

2,727

Goodwill

   

1,526

 

1,526

Other assets

   

628

 

632

Total assets

   

$       177,158

 

$            182,457

       

Liabilities

      

Current liabilities

      

Trade payable

   

8,889

 

8,518

Accrued liabilities

   

7,723

 

5,846

Income taxes payable

 

7,747

 

2,120

Derivative liabilities

   

8,669

 

3,960

Current portion of notes payable

634

 

619

Current portion of lease obligations

2,657

 

2,500

Total current liabilities

   

36,319

 

23,563

    

-

  

Notes payable

   

55,459

 

53,674

Lease obligations

   

21,573

 

21,091

Deferred tax liability

   

21,259

 

21,563

Total liabilities

   

134,610

 

119,891

       

Shareholders' equity

     

Share capital

   

180,792

 

180,657

Share-based compensation reserve

6,276

 

6,176

Equity conversion feature

 

6,677

 

4,933

Warrants

   

28,939

 

28,869

Accumulated deficit

   

(179,802)

 

(157,649)

Foreign currency translation reserve

(334)

 

(421)

Total shareholders' equity 

 

42,548

 

62,565

       

Total liabilities and shareholders' equity

$       177,158

 

$            182,457

CANSORTIUM INC.

          

STATEMENT OF OPERATIONS

      

FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020

           
    

 For the three months ended
June 30, 

 

 For the six months ended
June 30, 

     
    

2022

 

2021

 

2022

 

2021

           

Revenue, net of discounts

   

$         22,416

 

$              16,469

 

$           42,128

 

$         31,584

Cost of goods sold

   

7,405

 

5,745

 

15,571

 

11,152

           

Gross profit before fair value adjustments

15,011

 

10,724

 

26,557

 

20,432

           

Fair value adjustments on inventory sold

(8,594)

 

(4,727)

 

(15,418)

 

(9,320)

Unrealized gain on changes in fair value of biological assets

9,467

 

(1,224)

 

10,666

 

5,655

Gross profit

   

15,884

 

4,773

 

21,805

 

16,767

           

Expenses

          

General and administrative

2,319

 

2,868

 

5,160

 

6,156

Share-based compensation

-

 

285

 

100

 

3,517

Sales and marketing

  

4,190

 

3,515

 

8,277

 

7,061

Depreciation and amortization

1,694

 

1,547

 

3,358

 

3,078

Total expenses

   

8,203

 

8,215

 

16,895

 

19,812

           

(Loss) income from operations

   

7,681

 

(3,442)

 

4,910

 

(3,045)

           

Other expense (income)

          

Finance costs, net

   

3,843

 

4,719

 

7,500

 

7,849

Loss (gain) on change in fair value of derivative liability

3,007

 

(1,143)

 

4,709

 

(1,551)

Equity loss on investment in associate

-

 

-

 

-

 

-

Private Placement issuance expense

-

 

6,640

 

-

 

6,640

Loss on debt settlement

 

1,136

 

10,751

 

1,136

 

10,751

Loss on disposal of assets

   

-

 

1

 

-

 

50

Other (income) expense 

   

(373)

 

(18)

 

(373)

 

(131)

Total other expense

   

7,613

 

20,950

 

12,971

 

23,608

           

Loss before income taxes

 

68

 

(24,392)

 

(8,061)

 

(26,653)

           

Income tax expense

  

3,504

 

594

 

5,516

 

3,431

           

Net loss from continuing operations

(3,436)

 

(24,986)

 

(13,577)

 

(30,084)

           

Net loss (income) from discontinued operations

   

8,574

 

33

 

8,576

 

31

           

Net loss

   

$        (12,010)

 

$             (25,019)

 

$         (22,153)

 

$        (30,115)

           

Other comprehensive gain that may be reclassified 

to profit or loss in subsequent years

    

Exchange differences on translation of foreign operations
and reporting currency

   

62

 

(16)

 

87

 

(11)

           

Comprehensive loss

   

$        (11,948)

 

$             (25,035)

 

$         (22,066)

 

$        (30,126)

           

Net loss per share

          

Basic and diluted - continuing operations

$            (0.05)

 

$                 (0.11)

 

$              (0.09)

 

$            (0.14)

           
           

Weighted average  number of shares

    

Basic number of shares

 

252,276,742

 

225,401,664

 

252,276,742

 

213,945,477

Diluted number of shares

 

308,755,503

 

274,403,491

 

307,984,934

 

246,123,568

CANSORTIUM INC.

  

STATEMENTS OF CASH FLOWS

 

(USD '000)

  
   
 

 For the six months ended June 30, 

 

2022

2021

Operating activities

  

Net loss from continuing operations

$                      (22,153)

$                      (30,115)

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

  

Unrealized gain on changes in fair value of biological assets

(10,666)

(5,655)

Realized gain on changes in fair value of biological assets

15,418

9,320

Share-based compensation

100

3,517

Depreciation and amortization

6,072

4,675

Accretion and interest of convertible debentures

-

2,242

Interest and debt issuance costs of term loan

6,219

-

Interest income on notes receivable

(71)

-

Loss on disposal of assets

-

50

Loss on debt settlement

1,136

10,751

Discontinued operations 

8,576

31

Change in fair market value of derivative

4,709

(1,551)

Interest on lease liabilities

1,310

1,239

Deferred tax expense

(304)

959

Changes in operating assets and liabilities:

Trade receivable

(33)

26

Inventory

1,044

(554)

Biological assets

(9,290)

(4,246)

Prepaid expenses and other current assets

117

1,875

Other assets

5

(61)

Trade payable

374

(278)

Accrued liabilities

1,877

(651)

Income taxes payable

5,627

(10,523)

Net cash provided by (used in) operating activities

10,067

(18,949)

   

Investing activities

  

Purchases of property and equipment

(4,214)

(8,408)

Payment of notes receivable

119

284

Proceeds from sale of property and equipment

-

24

Advances for notes receivable 

(94)

(1,020)

Net cash used in investing activities

(4,189)

(9,120)

   

Financing activities

  

Proceeds from issuance of shares and warrants

-

23,730

Proceeds from issuance of debt, net of loan issuance costs

-

63,133

Proceeds from issuance of convertible debenture and warrants

4,656

-

Payment of lease obligations

(2,521)

(2,154)

Exercise of Options

135

-

Exercise of warrants

-

1,365

Principal repayments of notes payable

-

(35,382)

Repayments of principal and interest of Senior Secure Term loan

(8,401)

-

Net cash provided by (used in) financing activities

(6,131)

50,692

Effect of foreign exchange on cash and cash equivalents

87

(11)

Net increase (decrease) in cash and cash equivalents

(166)

22,612

Cash and cash equivalents, beginning of period

9,024

3,392

Cash and cash equivalents, end of period

$                          8,858

$                       26,004

CANSORTIUM INC.

 

ADJUSTED EBITDA RECONCILIATION

 

(USD '000)

 
 

Three months ended

 

June

June

Variance

 

30, 2022

30, 2021

Net loss

$      (12,010)

$      (25,019)

$      13,009

Finance costs, net

3,843

4,719

(876)

Income taxes

3,504

594

2,910

Depreciation and amortization

3,366

2,429

937

EBITDA

$         (1,297)

$      (17,277)

$      15,980

    
    
 

Three months ended

 

June
30, 2022

June
30, 2021

Variance

EBITDA

$         (1,297)

$      (17,277)

$      15,980

Change in fair value of biological assets

(873)

5,951

(6,824)

Change in fair market value of derivative

3,007

(1,143)

4,150

Loss on debt settlement

1,136

10,751

(9,615)

Private placement issuance expense

-

6,640

(6,640)

Share-based compensation

-

285

(285)

Discontinued operations

8,574

33

8,541

Loss on disposal of assets

-

1

(1)

Other non-recurring expense/(income)

(373)

(18)

(355)

Adjusted EBITDA

$        10,174

$          5,223

$        4,951

Plug Into More Green Stock News

Tap into the pulse of emerging green sectors every morning. Top daily headlines from clean energy, cleantech, cannabis, and sustainable transport stocks:

Please review our Disclaimer and Privacy Policy before subscribing. One-click unsubscribe at any time.
Northstar Clean Technologies

Northstar Clean Technologies is a cleantech company focused on the sustainable recovery and reprocessing of asphalt shingles. Northstar’s mission is to be the leader in the recovery and reprocessing of asphalt shingles in North America...

CLICK TO LEARN MORE
Else Nutrition

Else Nutrition is changing the face of early childhood nutrition with clean, sustainable, plant-based products. The company has developed the world’s first whole plant-based infant formula that is targeting the $100+ billion global...

CLICK TO LEARN MORE

COPYRIGHT ©2022 GREEN STOCK NEWS